Tumor necrosis by pretreatment breast MRI: association with neoadjuvant systemic therapy (NAST) response in triple-negative breast cancer (TNBC)
Abeer H. Abdelhafez(The University of Texas MD Anderson Cancer Center), Gaiane M. Rauch(The University of Texas MD Anderson Cancer Center), Ken‐Pin Hwang(The University of Texas MD Anderson Cancer Center), Peng Wei(Creighton University), Marion E. Scoggins(The University of Texas MD Anderson Cancer Center), Lumarie Santiago(Nektar Therapeutics (United States)), Jennifer K. Litton(The University of Texas MD Anderson Cancer Center), Jason B. White(The University of Texas MD Anderson Cancer Center), Elsa Arribas(The University of Texas MD Anderson Cancer Center), Alastair M. Thompson(Baylor College of Medicine), Jessica W. T. Leung(The University of Texas MD Anderson Cancer Center), Deanna L. Lane(The University of Texas MD Anderson Cancer Center), Stacy L. Moulder(The University of Texas MD Anderson Cancer Center), Jong Bum Son(The University of Texas MD Anderson Cancer Center), Rosalind P. Candelaria(The University of Texas MD Anderson Cancer Center), Tanya W. Moseley(The University of Texas MD Anderson Cancer Center), Benjamin C. Musall(Henry Ford Health System), Beatriz E. Adrada(The University of Texas MD Anderson Cancer Center), Huong T. Le‐Petross(The University of Texas MD Anderson Cancer Center), Vicente Valero(The University of Texas MD Anderson Cancer Center), Wei Yang(Shanghai Jiao Tong University), Elizabeth E. Ravenberg(Eli Lilly (United States)), Jingfei Ma(The University of Texas MD Anderson Cancer Center), Mark D. Pagel(University of Wisconsin–Madison), Hagar S. Mahmoud(The University of Texas MD Anderson Cancer Center), KennethR. Hess(The University of Texas MD Anderson Cancer Center), Gary J. Whitman(The University of Texas MD Anderson Cancer Center)
Cited by 15
Related Papers
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
|New England Journal of Medicine|2016|2k
Comparison and integration of deleteriousness prediction methods for nonsynonymous SNVs in whole exome sequencing studies
|Human Molecular Genetics|2014|1.2k
Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2021|1.1k
Breast Cancer Before Age 40 Years
|Seminars in Oncology|2009|795
NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017
|Journal of the National Comprehensive Cancer Network|2016|660